These findings suggest that JOA is efficacious against BCR-ABL-native CML cells and BaF3 cell lines bearing T315I mutations of BCR-ABL via inducing cell differentiation associated with the inhibition of BCR-ABL and c-MYC. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.